A special omega-3 fatty acid lipid will change how we look at the developing and aging brain

An insulating membrane encasing nerves, myelin sheaths facilitate the quick and effective conduction of electrical signals throughout the body's nervous system. When the myelin sheath gets damaged, nerves may lose their ability to function and cause neurological disorders. With aging, myelin sheaths may naturally start to degenerate, which is often why the elderly lose their physical and mental abilities.

"Loss of myelin sheaths occurs during the normal ageing process and in neurological diseases, such as multiple sclerosis and Alzheimer's disease," said Dr. Sengottuvel Vetrivel, Senior Research Fellow with Duke-NUS' Cardiovascular & Metabolic Disorders (CVMD) Programme and lead investigator of the study. "Developing therapies to improve myelination -- the formation of the myelin sheath -- in ageing and disease is of great importance to ease any difficulties caused by declining myelination."

To pave the way for developing such therapies, the researchers sought to understand the role of Mfsd2a, a protein that transports lysophosphatidylcholine (LPC) -- a lipid that contains an omega-3 fatty acid -- into the brain as part of the myelination process. From what is known, genetic defects in the Mfsd2a gene leads to significantly reduced myelination and a birth defect called microcephaly, which causes the baby's head to be much smaller than it should be.

In preclinical models, the team showed that removing Mfsd2a from precursor cells that mature into myelin-producing cells -- known as oligodendrocytes -- in the brain led to deficient myelination after birth. Further investigations, including single-cell RNA sequencing, demonstrated that Mfsd2a's absence caused the pool of fatty acid molecules -- particularly omega-3 fats -- to be reduced in the precursor cells, preventing these cells from maturing into oligodendrocytes that produce myelin.

"Our study indicates that LPC omega-3 lipids act as factors within the brain to direct oligodendrocyte development, a process that is critical for brain myelination," explained Professor David Silver, the senior author of the study and Deputy Director of the CVMD Programme. "This opens up potential avenues to develop therapies and dietary supplements based on LPC omega-3 lipids that might help retain myelin in the ageing brain -- and possibly to treat patients with neurological disorders stemming from reduced myelination."

Previously, Prof Silver and his lab discovered Mfsd2a and worked closely with other teams to determine the function of LPC lipids in the brain and other organs. The current research provides further insights into the importance of lipid transport for oligodendrocyte precursor cell development.

"We're now aiming to conduct preclinical studies to determine if dietary LPC omega-3 can help to re-myelinate damaged axons in the brain," added Prof Silver. "Our hope is that supplements containing these fats can help to maintain -- or even improve -- brain myelination and cognitive function during ageing."

"Prof Silver has been relentless in investigating the far-reaching role of Msdf2a ever since he discovered this important lipid transport protein, alluding to the many possible ways of treating not only the ageing brain but also other organs in which the protein plays a role," said Professor Patrick Casey, Senior-Vice Dean for Research. "It's exciting to watch Prof Silver and his team shape our understanding of the roles that these specialised lipids play through their many discoveries."